Possibilities of COC-DRSP in women with stress-dependent menstrual irregularities
https://doi.org/10.33667/2078-5631-2021-26-23-27
Abstract
Purpose of the study. Evaluation of the effectiveness and safety of COC-DRSP in the control of psychosomatic symptoms in women with stressdependent menstrual irregularities.
Materials and methods. The observational study involved 28 women aged 18 to 39 years with somatoform anxiety disorder and menstrual irregularities resulting from stressful events and did not have a tendency to improve in the process of therapeutic lifestyle modification and the use of means to improve adaptation. In order to prevent pregnancy and control the menstrual cycle, the patients were prescribed a combined oral contraceptive containing drospirenone (DRSP-COC) in the «24 + 4» regimen. Prior to the study, 3 and 6 months after initiation of therapy, psychosomatic symptoms of anxiety disorder were assessed.
Results. Reception of DRSP-COC (Dimia) led to a significant decrease in the frequency and severity of psychosomatic symptoms after three cycles of therapy with the preservation of the effect with continued administration.
Conclusion. DRSP-COC is effective in relieving psychosomatic symptoms in women with stress-related menstrual irregularities.
About the Authors
N. Kh. Khadzhieva
Central Clinical Hospital ‘Russian Railways – Medicine’
Russian Federation
Russian Federation
Khadzhieva Nyurzhanna Kh., obstetrician-gynecologist
Moscow
I. V. Kuznetsova
National Medical Research Centre for Obstetrics, Gynecology and Perinatology n.a. academician V.I. Kulakov
Russian Federation
Russian Federation
Kuznetsova Irina V., DM Sci, professor, director’s advisor
Moscow
References
1. Sharma R, Biedenharn KR, Fedor JM, Agarwal A. Lifestyle factors and reproductive health: taking control of your fertility. Reprod Biol Endocrinol. 2013; 11: 66. DOI: 10.1186/1477–7827–11–66.
2. Joseph DN, Whirledge S. Stress and the HPA Axis: Balancing Homeostasis and Fertility. Int J Mol Sci. 2017; 18 (10): 2224. DOI: 10.3390/ijms18102224.
3. Lucassen PJ, Pruessner J, Sousa N, Almeida OF, Van Dam AM, Rajkowska G, et al. Neuropathology of stress. Acta Neuropathol. 2014; 127 (1): 109–35. DOI: 10.1007/s00401–013–1223–5.
4. Stenyaeva N.N., Khritinin D. F., Grigoriev V. Yu., Kuzemin A.A. Sex steroids and brain function. Gynecology. 2017; 19 (2): 9–14.
5. Goel N, Workman JL, Lee TT, Innala L, Viau V. Sex differences in the HPA axis. Compr Physiol. 2014 Jul; 4 (3): 1121–55. DOI: 10.1002/cphy.c130054. PMID: 24944032.
6. Labombarda F, Garcia-Ovejero D. Give progesterone a chance. Neural Regen Res 2014; 9 (15): 1422–4. DOI: 10.4103/1673–5374.139456.
7. Kubasov R. V., Barachevsky Yu.E., Lupachev V. V. Functional changes in the pituitary-gonadal and thyroid endocrine links in response to stress factors. Basic research. 2014; 10: 1010–1014.
8. Toufexis D, Rivarola MA, Lara H, Viau V. Stress and the reproductive axis. J Neuroendocrinol. 2014; 26 (9): 573–586. DOI: 10.1111/jne.12179.
9. Valsamakis G, Chrousos G, Mastorakos G. Stress, female reproduction and pregnancy. Psychoneuroendocrinology. 2019; 2 (100): 48–57 DOI: 10.1016/j.psyneuen.2018.09.031.
10. Dome P, Tombor L, Lazary J, Gonda X, Rihmer Z. Natural health products, dietary minerals and over-the-counter medications as add-on therapies to antidepressants in the treatment of major depressive disorder: a review. Brain Res Bull. 2019; 146: 51–78. DOI: 10.1016/j.brainresbull.2018.12.015.
11. Pattanittum P, Kunyanone N, Brown J, Sangkomkamhang US, Barnes J, Seyfoddin V, Marjoribanks J. Dietary supplements for dysmenorrhoea. Cochrane Database Syst Rev. 2016; 3 (3): CD002124. DOI: 10.1002/14651858.CD002124.pub2.
12. McCabe D. The impact of essential fatty acid, B vitamins, vitamin C, magnesium and zinc supplementation on stress levels in women: a systematic review. JBI Database System Rev Implement Rep, 2017 DOI: 10.11124/JBISRIR2016–002965.
13. Gromova O.A., Torshin I. Yu., Tetruashvili N.K. The use of riboflavin and magnesium citrate in obstetrics and gynecology. Gynecology. 2018; 20 (6): 60–66.
14. Caumo W, Hidalgo MP, Souza A, Torres ILS, Antunes LC. Melatonin is a biomarker of circadian dysregulation and is correlated with major depression and fibromyalgia symptom severity. J Pain Res. 2019; 12: 545–556. DOI: 10.2147/JPR.S176857.
15. Giribela CR, Consolim-Colombo FM, Nisenbaum MG. Effects of a combined oral contraceptive containing 20 mcg of ethinylestradiol and 3 mg of drospirenone on the blood pressure, renin-angiotensin-aldosterone system, insulin resistance, and androgenic profile of healthy young women. Gynecol Endocrinol. 2015; 31 (11): 912–915 DOI: 10.3109/09513590.2015.1062860.
16. Machado RB, Pompei Lde M, Giribela AG, Giribela CG. Drospirenone/ethinylestradiol: a review on efficacy and noncontraceptive benefits. Womens Health (Lond). 2011; 7 (1): 19–30. DOI: 10.2217/whe.10.84.
17. Tverdikova M.A., Gavisova A.A. Drospirenone is a reliable contraception and non-contraceptive effects. Breast cancer. 2012; 1: 1–5.
18. Kuznetsova I.V., Konovalov V.A. Menstrual irregularities and their hormonal correction in the context of stress-dependent psycho-vegetative disorders. Medical Advice. 2014; 9: 12–16. DOI: 10.21518/2079–701X2014–9–12–16.
19. Takimoto-Ohnishi E, Murakami K. Renin-angiotensin system research: from molecules to the whole body. J Physiol Sci. 2019; 69 (4): 581–587. DOI: 10.1007/s12576–019–00679–4.
20. Unanyan A. L., Sidorova I. S., Kuzenkova N.N. Premenstrual syndrome: etiopathogenesis, classification, clinical picture, diagnosis and treatment. Breast cancer. Mother and Child. 2018; 2 (1): 34–38.
21. Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev. 2012; (2): CD006586. DOI: 10.1002/14651858.CD006586.pub4.
22. Lundin C, Danielsson KG, Bixo M, Moby L, Bengtsdotter H, Jawad I, et al. Combined oral contraceptive use is associated with both improvement and worsening of mood in the different phases of the treatment cycle-A double-blind, placebo-controlled randomized trial. Psychoneuroendocrinology. 2017; 76: 135–143. DOI: 10.1016/j.psyneuen.2016.11.033.
23. Gordon CM, Ackerman KE, Berga SL, Kaplan JR, Mastorakos G, Misra M, et al. Functional Hypothalamic Amenorrhea: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2017; 102 (5): 1413–1439. DOI: 10.1210/jc.2017–00131.
Review
For citations:
Khadzhieva N.Kh., Kuznetsova I.V. Possibilities of COC-DRSP in women with stress-dependent menstrual irregularities. Medical alphabet. 2021;(26):23-27. (In Russ.) https://doi.org/10.33667/2078-5631-2021-26-23-27
Views:
583
Email this article 